Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of achievable remissions and clinical variables that influence the outcome of sorafenib monotherapy are largely undefined. To address these questions, we evaluated sorafenib monotherapy in 65 FLT3-ITD AML patients treated at 23 centers. All but two patients had relapsed or were chemotherapy-refractory after a median of three prior chemotherapy cycles. Twenty-nine patients (45%) had undergone prior allogeneic stem cell transplantation (allo-SCT). The documented best responses were: hematological remission in 24 patients (37%), bone marrow remission in 5 patients (8%), complete remission (with and without normalization of peripheral blood counts) in 15 patients (23%) and molecular remission with undetectable FLT3-ITD mRNA in 10 patients (15%), respectively. Seventeen of the patients without prior allo-SCT (47%) developed sorafenib resistance after a median treatment duration of 136 days (range, 56-270 days). In contrast, allo-SCT patients developed sorafenib resistance less frequently (38%) and significantly later (197 days, range 38-225 days; P ¼ 0.03). Sustained remissions were seen exclusively in the allo-SCT cohort. Thus, sorafenib monotherapy has significant activity in FLT3-ITD AML and may synergize with allogeneic immune effects to induce durable remissions.
INTRODUCTION
Long-term survival of acute myeloid leukemia (AML) patients is 30-70% in younger individuals, and less than 15% in the elderly population. 1 In patients with normal karyotype AML, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene represent one of the most frequently observed genetic alterations. About 20-25% of young patients with AML show specific in-frame internal tandem duplications of 3-400 bp in various domains of the FLT3 kinase receptor (FLT3-ITD) gene, leading to a constitutive activation of FLT3 and aberrant activation of multiple downstream signaling pathways (reviewed by Kindler et al. 2 ). FLT3-ITD is significantly associated with a poor outcome. [3] [4] [5] Clinical but also multiple lines of experimental evidence suggest FLT3 as rational target for therapeutic intervention. 6, 7 Accordingly, various FLT3 inhibitors have been tested in clinical trials, both as monotherapy or in combination with chemotherapy. 2 It was shown that FLT3 inhibitors were only marginally effective in unselected AML, whereas responses were more frequently observed in patients harboring mutant FLT3. [8] [9] [10] For example, in the first phase I trial, testing the FLT3 inhibitor sorafenib (Nexavar, formerly BAY 43-9006) in AML only FLT3-ITD-positive (FLT3-ITD), but not FLT3-ITD-negative AML patients responded. 11 Three subsequent phase I studies underscored this evidence by demonstrating consistent activity of sorafenib in relapsed and refractory FLT3-ITD AML, while primary resistance was frequently seen in AML expressing the wild-type form of FLT3. [12] [13] [14] Thus, although sorafenib simultaneously blocks FLT3 and multiple other kinases, such as the serine threonine kinase Raf-1, plateletderived growth factor receptor and vascular endothelial growth factor receptor, 15 its most relevant target in AML appears to be FLT3-ITD.
Although sorafenib responses in FLT3-ITD AML patients are usually transient, 11, 13, 14, 16 we and others have previously published several cases with relapsed FLT3-ITD AML who showed extended remissions under sorafenib monotherapy. 17, [18] [19] [20] [21] [22] [23] This stimulated us to gain a better understanding of the value of sorafenib monotherapy in FLT3-ITD AML-in particular with respect to the circumstances where complete and long-lasting remissions may be obtained.
Based on this largest retrospective analysis of FLT3-ITD AML patients published to-date, we hypothesize that durable remissions to sorafenib monotherapy depend on a synergism with allo-immune mechanisms implemented by allogeneic stem cell transplantation (allo-SCT). This may stimulate the design of future therapeutic concepts incorporating FLT3-inhibitors in AML therapy.
PATIENTS AND METHODS

Study objective
The primary objective of this study was to assess the time to treatment failure of a 'compassionate use' sorafenib monotherapy in relapsed, chemotherapy-refractory or frail FLT3-ITD AML patients who were ineligible for any alternative treatments. Patients were stratified into two cohorts. Patients were categorized into an allo-SCT cohort or a conventional therapy cohort (CT), depending on whether or not they had undergone allo-SCT before receiving sorafenib. Secondary study objectives were the assessment of the best response, tolerability and side effects to sorafenib.
Study design
This was a retrospective survey. The study population consisted exclusively of FLT3-ITD AML patients who were treated with sorafenib as monotherapy. To assess study objectives, a questionnaire was developed, approved by the local ethics committee of the Philipps University Marburg and sent to 45 national and international centers treating AML patients. Patient information was anonymously documented and included age, gender, FAB-classification, karyotype, FLT3 mutation status, presence or absence of concurrent molecular markers, response to prior therapies (including allo-SCT), sorafenib dosing, tolerability, treatment duration and quality of best response.
Response definition
Treatment response was evaluated according to the Cheson criteria and as previously described. 17, 24 In brief, the following responses were defined: (i) complete remission (CR): marrow blastso5%, neutrophils41 Â 10 9 /l, platelets4100 Â 10 9 /l; (ii) CR with incomplete peripheral blood count recovery (CRi); (iii) bone marrow response: marrow blasts reduction by450% from start of sorafenib without hematologic recovery; (iv) hematologic response (HR): disappearance of blasts from the peripheral blood; (v) partial response (PR): peripheral blasts reduction by450%; (vi) complete molecular response (CMR): CR plus molecular negativity for FLT3-ITD mRNA by PCR.
Time to treatment failure, definition of relapse, censoring Time to sorafenib treatment failure was defined as the time interval between commencing sorafenib and emergence of sorafenib resistance. Sorafenib resistance was defined as the time point of relapse, that is, (i) a confirmed blast increase in peripheral blood and/or bone marrow or (ii) a confirmed molecular increase in the FLT3-ITD copy number despite ongoing sorafenib treatment.
Censoring occurred in case of loss to follow-up, changing of sorafenib therapy to an alternative treatment (as in the case of bridging to allo-SCT) or death that was unrelated to a sorafenib resistance.
Statistical analysis
Statistical analysis was performed using Prism Software, Version 5.0b (GraphPad Software, Inc., La Jolla, CA, USA). The median time to treatment failure was estimated from the time of sorafenib start until relapse with ongoing sorafenib treatment using Kaplan-Maier curves.
Analysis of a statistical difference between the curves was performed using the two-tailed log-rank (Mantel-Cox) test.
RESULTS
Data collection
Questionnaires were returned from 29 national and international centers, reporting 89 patients. A total of 24 documentation forms were excluded from further evaluation, because they included FLT-ITD-negative patients (n ¼ 9) or patients that had received sorafenib in CR as maintenance therapy (n ¼ 2) or additional chemotherapy in the context of sorafenib (n ¼ 13). However, patients that had been switched to sorafenib because of chemotherapy-refractory disease on day þ 15 of induction therapy or due to progressive disease under chemotherapy were included in the survey.
Patient's demographics and treatment characteristics are shown in Tables 1 and 2 Pretreatment characteristics A total of 65 FLT3-ITD AML patients (38 females, 27 males) were included in this retrospective analysis. Patients were categorized and separately analyzed according to the characteristics of their pretreatments (Table 2) . There were 36 patients in the CT group: 34 patients had relapsed after prior chemotherapy, whereas 2 patients were treated upfront with sorafenib. The second cohort consisted of 29 patients. They received sorafenib as rescue therapy for relapsing AML after allo-SCT (allo-SCT group). One patient in the allo-SCT group (patient 1) was treated in molecular relapse after allo-SCT with a confirmed increase in FLT3-ITD mRNA copy numbers. In the allo-SCT group, three patients had received sorafenib even before allo-SCT (patients 2, 14 and 28).
Sorafenib was initiated at diagnosis (n ¼ 2), after primary
The median number of previous chemotherapy treatment cycles was three (range, 0-9 cycles) considering each cycle of induction, consolidation, relapse and conditioning therapy before allo-SCT as one chemotherapy cycle (for details, see Table 2 and Figure 1 ). The median number of prior chemotherapy cycles was two in the CT group compared with four in the allo-SCT group.
Sorafenib treatment details
The median sorafenib treatment duration was 74 days (range, 1-270) in the CT cohort and 76 days (range, 14-904) in the allo-SCT group. In 42 patients (23 allo-SCT, 19 CT), sorafenib was commenced with the approved standard dose of 2 Â 400 mg sorafenib p.o. daily. Sorafenib dose was increased to 800 mg daily in the course of the therapy in four patients (one allo-SCT, three CT). In three patients (patients 1, 2 and 4) sorafenib was stopped in CR after a treatment duration of 761, 546 and 85 days, respectively.
The median dose of sorafenib was 600 mg daily in the allo-SCT and 486.5 mg daily in the CT group. Sorafenib dose reductions and interruptions were carried out in 40 patients for suspected toxicity as to the discretion of the treating physician. Main reasons for dose modifications were toxicity such as WHO grade III-IV cytopenia (n ¼ 19), infectious complications (n ¼ 8), skin toxicity (n ¼ 6), hand-foot-syndrome (n ¼ 3) and mucositis (n ¼ 5). In eight patients, sorafenib was permanently stopped due to infectious complications (n ¼ 4), suspected graft versus host disease of the skin (n ¼ 2), hand-foot-syndrome (n ¼ 1), neurotoxicity (n ¼ 1) and suspected cardiac decompensation (n ¼ 1). However, sorafenib was restarted or dose escalated in 20 of these 40 patients.
Evaluation of sorafenib-associated toxicities In this cohort of patients with overt AML, sorafenib was generally well tolerated. Pancytopenia of WHO grade III and IV (n ¼ 40, 62%) was the most frequently reported severe side effect. However, cytopenia also reflected response to therapy as it resolved after ongoing treatment in four hyperleukocytotic and three chemotherapy-refractory cytopenic AML patients. Other suspected Table 2 . Auto, autologous stem cell transplantation; CMR, complete molecular remission; Ctx, chemotherapy; IFN, interferon alpha; SCT, allogenic stem cell transplantation; SCT(syn), syngeneic transplantation; Tox, severe sorafenib toxicity.
sorafenib-mediated toxicities were infectious complications (n ¼ 17), exanthema (n ¼ 12), hand-foot-syndromes (n ¼ 8), mucositis (n ¼ 7), hepatotoxicity (n ¼ 5), arterial hypertension (n ¼ 4, including one concomitant angina pectoris), suspected cardiac decompensations (n ¼ 2), gastrointestinal perforation (n ¼ 1), gastrointestinal bleeding (n ¼ 1), intracranial bleeding (n ¼ 1), neurotoxicity (n ¼ 1) and non-specified cardiac arrhythmia (n ¼ 1). Among these toxicities infections (n ¼ 9), cardiac decompensation (n ¼ 1), gastrointestinal perforation (n ¼ 1) and intracranial bleeding (n ¼ 1) were associated with a fatal outcome in 10 patients. Among patients having undergone allo-SCT, one case with severe liver, one with suspected severe skin and five cases with mild graft versus host disease (ograde II) were reported. Minor sorafenib side effects such as diarrhea, alopezia and nausea were also documented.
Quality of sorafenib-induced responses All 65 patients but one achieved at least a HR (n ¼ 54) or PR (n ¼ 10) characterized by complete or 450% peripheral blast clearance, respectively. In all, 2 of the 10 PR patients had a pretherapeutic WBC of 4150 G/l and received only 1 and 9 days of therapy, respectively. The documented best responses to sorafenib were HR only (n ¼ 24) HR and bone marrow response (n ¼ 5), CRi (n ¼ 13), and CR (n ¼ 2). Ten CR patients became FLT3-ITD mRNA-negative by reverse transcriptase PCR in the peripheral blood (that is, CMR; Table 1 ).
There were more CMR patients in the allo-SCT cohort (7/29; 24%) than in the CT group (3/36; 8%; Table 1 ). Another clinically important aspect was the finding that sorafenib bridged one relapsed and six primary refractory FLT3-ITD AML patients (patients 2, 37, 49, 50, 52, 55 and 56) for a median of 63 days (range, 14-138) from the start of sorafenib until allo-SCT. Four relapsed patients after first allo-SCT, two of them chemotherapyrefractory, were bridged for a median of 58 days (range, 20-94) until a second allo-SCT could be performed (patients 16, 18, 24 and 27). Together, a rate of 38% CRis, CRs and CMRs (25 patients) in an extremely poor risk cohort of AML patients underscores that sorafenib monotherapy can exert clinically meaningful activity in FLT3-ITD AML patients ( Table 2 ).
Durability of sorafenib responses
In all, 28 of the 65 patients (43%) developed clinical sorafenib resistance as defined in the Patients and methods section. The median time to emergence of sorafenib resistance was 160 days (Table 1) . However, the median time to sorafenib resistance in the allo-SCT group was 197 days (range, 38-225) and thus significantly longer as compared with the CT group, in which resistance emerged after a median of 136 days (range, 56-270; P ¼ 0.0305). Importantly, the proportion of patients who developed clinical sorafenib resistance at any time was less than in the allo-SCT group. In all, 17 of 36 (47%) patients in the CT group versus 11 of 29 (38%) patients of the allo-SCT group developed sorafenib resistance ( Figure 2 ).
DISCUSSION
In this study, we retrospectively evaluated therapy outcome of 65 FLT3-ITD AML patients under sorafenib monotherapy. This revealed two major findings. First, we confirm and significantly extend preliminary evidence showing that sorafenib monotherapy is efficacious in FLT3-ITD AML. Secondly, we show that sorafenibinduced remissions may be more frequent, deeper and more durable in FLT3-ITD AML patients relapsing after a prior history of allo-SCT ( Figure 2 and Table 1 ). We conclude that there is an antileukemic synergism between sorafenib and allo-immune effects exerted by the stem cell graft.
Even though our conclusions were based on retrospective data, a detailed and critical analysis of the latter provided valuable new information. For example, the consistency of responses under sorafenib (including bone marrow response, CRi, CR and CMR) that were seen in a very poor risk category of AML, with on average three cycles of prior chemotherapies, significantly corroborated previous evidence that patients harboring mutated FLT3-ITD have a high likelihood to respond to FLT3 inhibition with sorafenib as well as other tyrosine-kinase inhibitors given as monotherapy. 8, 9, [25] [26] [27] This is an important information in light of the fact that there still is no evidence that FLT3 inhibitors-including sorafenib-improve the outcome of AML. In fact, a combination of sorafenib and chemotherapy was of no benefit in two independent trials, although in these trials more than two thirds of the included patients were FLT3-ITD-negative. 28, 29 There was also no effect on overall or progression-free survival for patients that were treated with a combination of an alternative FLT3 inhibitor, lestaurtinib (CEP701) and chemotherapy. 30 This study was negative despite the fact that all recruited patients harbored mutated FLT3 (490% FLT3-ITD). Lestaurtinib's complex pharmacokinetics and toxic off-target effects, but also its combination with chemotherapy, may have contributed to the disappointing outcome. 30 How could chemotherapy compromise the effects of FLT3 inhibitors? As one mechanism it has been suggested that AML chemotherapy leads to elevated serum levels of the FLT3-ligand that presumably induces kinase inhibitor drug resistance by autocrine stimulation of FLT3-ITD. 30, 31 Thus, although FLT3-ITD has been recognized as a bona fide target for therapeutic intervention with kinase inhibitors, beneficial treatment combinations, optimal treatment time points and algorithms to integrate FLT3 inhibitors are still undefined.
In this regard, it was an important finding of this survey that relapsed allo-SCT patients fared better with sorafenib than CT patients, because sorafenib-induced remissions in allo-SCT patients lasted on average significantly longer than in CT patients ( Figure 2 and Table 1 ).
In fact, none of the CT patients survived for more than 9 months on sorafenib without emergence of resistance, as of to date three patients in the allo-SCT cohort survived already for more than 2 years relapse-free. This notion is also in keeping with other reports showing long-term survival of sorafenib-treated FLT3-ITD patients relapsing after allo-SCT. 32, 33 A reporting bias in favor of preferably documenting good responses of allo-SCT patients in our survey seemed not likely, because CR/CMR patients in the CT group would have had the same chance of being reported. Based on this, we propose a potentially curative synergism between the kinase inhibitor sorafenib and allo-immune-mediated anti-leukemic Figure 2 . Comparison of time to treatment failure (TTF) according to therapy group as indicated. TTF of patients in the conventional therapy group was significantly shorter than of those in the allo-SCT cohort (P ¼ 0.0305). Censored events are indicated and included patients that were lost to follow-up, changed therapy or died for reasons that were unrelated to sorafenib resistance. effects, as previously exemplified by the use of the BCR-ABL inhibitor imatinib after allo-SCT in chronic myeloid leukemia. 34 Whether a putative synergism is due to a direct stimulation of allo-reactive immune functions by sorafenib or a reduction of the tumor mass, enabling re-establishment of a graft versus leukemia reaction or both, is currently unknown. A recent concern that sorafenib may aggravate graft versus host disease 35 is not supported, but can also not be entirely excluded by our data. Sharma et al described no benefit from sorafenib application posttransplantation in a group of 16 FLT3-ITD þ AML patients relapsing after allo-SCT. 36 This may be explained by different patient characteristics. For example, patients in their study were more frequently pretreated with sorafenib (38% versus 10% in our group) had undergone a second allo-SCT (25% versus 0%) received less frequently sorafenib as first salvage therapy in relapse after allo-SCT (56% versus 72%) or were given sorafenib concomitantly with chemotherapy (50% versus 0%).
Only eight patients in our survey discontinued sorafenib for toxicity reasons. Although the most commonly observed side effect was cytopenia, hematological recovery was frequently noted despite ongoing sorafenib exposure. Thus, it may not be justified to pause or dose-reduce sorafenib in the case of treatment-associated cytopenia, as it can also not be excluded that this could limit treatment efficacy.
In summary, sorafenib monotherapy induces clinically meaningful responses in FLT3-ITD AML, but sustained remissions with sorafenib seem to depend on a synergism with allo-immune effects mediated by an allogenic stem cell graft. Based on our results, we here suggest for the first time that the prophylactic use of sorafenib after allo-SCT could be promising to prevent relapses. Since 2010, the 'SORMAIN' trial (EudraCT 2010-018539-16) recruits patients to prospectively address this question in a randomized, double-blind, placebo-controlled manner.
